Dr. Yentz on Unmet Needs in Metastatic RCC

Sarah Elizabeth Yentz, MD, clinical assistant professor, University of Michigan Health, medical oncologist, Brighton Center for Specialty Care, Rogel Cancer Center, Michigan Medicine, discusses unmet needs in metastatic renal cell carcinoma (mRCC).

Historically, patients with mRCC received a TKI followed by immunotherapy or immunotherapy followed by a TKI, Yentz explains. However, now that immunotherapy is being combined with TKIs, it is harder to select the optimal treatment approach for a patient who progresses beyond first-line therapy, Yentz says. Moreover, the second-line setting is an area with room to incorporate new therapies ​because patients continue to progress on regimens that are now utilized in the frontline setting, Yentz adds.

Ultimately, it is important to have a plan for a patient’s treatment course to guide what therapy is optimal upon progression, Yentz concludes.